User login
Endobronchial dysplasia significantly improved in former smokees who received oral iloprost during a phase II trial, says study investigator Dr. Robert Keith. Bob Finn of the Global Medical News Network (GMNN) reports from the World Conference on Lung Cancer in San Francisco.
Endobronchial dysplasia significantly improved in former smokees who received oral iloprost during a phase II trial, says study investigator Dr. Robert Keith. Bob Finn of the Global Medical News Network (GMNN) reports from the World Conference on Lung Cancer in San Francisco.
Endobronchial dysplasia significantly improved in former smokees who received oral iloprost during a phase II trial, says study investigator Dr. Robert Keith. Bob Finn of the Global Medical News Network (GMNN) reports from the World Conference on Lung Cancer in San Francisco.